With over 20 years of experience, Dr. Shieh-Newton plays a strategic role for her clients as she guides their patent strategy, portfolio management and investments. Trained as an immunologist at Johns Hopkins School of Medicine, where she earned a PhD in Cellular and Molecular Medicine, she works with companies of all sizes in a wide range of life sciences and clean technology industries. She also manages and conducts due diligence for companies and investors. Dr. Shieh-Newton is known for her creative, business-savvy solutions and collaborative work style.
Dr. Shieh-Newton leads and conducts due diligences for both private and public companies and investors. Dr. Shieh-Newton has been the primary IP counsel on many deals on behalf of investment bankers and underwriters for IPOs and other public offerings totaling >$1 billion. Dr. Shieh-Newton has also worked with companies on a number of reverse mergers and also drafted securities disclosures for offerings in the capital markets. She has also worked with venture capitalists on due diligence assessment for investments and landscape analysis for formation of new funds and companies.
In addition, Dr. Shieh-Newton’s practice includes assessing freedom-to-operate positions and rendering patentability and invalidity opinions. She has extensive experience in evaluating patent landscapes to advise clients seeking to enter competitive markets, as well as advising clients on third party challenges and risk mitigation strategies. Dr. Shieh-Newton has worked on biotechnology patent litigations, Oppositions, and IPRs.
Dr. Shieh-Newton has worked on a wide variety of technical areas including antibodies, biologics and biosimilars, immuno-oncology (including chimeric T-antigen receptors), immunotherapy, gene editing (e.g., CRISPR technology), stem cells, regenerative medicine, gene therapy, synthetic biology, microbiomes, enzymes, protein engineering, protein production and therapeutics, vaccines and adjuvants, diagnostics and biomarkers, cancer, biofuels, microbial engineering, industrial fermentation, production of target chemical using biological processes, quantum sensors, biological computations units, and artificial intelligence amongst other subject matters.
Dr. Shieh-Newton has worked with emerging companies, universities, as well as larger companies. Representative matters include work done for DuPont/Danisco/Genencor, Regeneron, Roche, Genentech, Goodyear Rubber & Tire Company, Ariosa, University of California, and Stanford University.
Dr. Shieh-Newton was trained as an immunologist at Johns Hopkins School of Medicine, where her doctoral research focused on the early immune responses to HIV and SIV infection. Dr. Shieh-Newton was a student fellow with Nobel Laureates Dr. Joseph Goldstein and Dr. Michael Brown, researching farnesylated ras proteins.
Dr. Shieh-Newton created and has hosted for the past three years an annual diversity event in the Bay Area. She is also an annually-featured speaker at the conference of SynBioBeta, an association focused on the promotion and support of the synthetic biologics, an industry in which Terri represents prominent clients like DuPont. Dr. Shieh-Newton was selected as one of the “100 Most Influential Women in Business in the Bay Area” by the San Francisco Business Times, identified among the “World’s Leading Patent Practitioners” in Intellectual Asset Magazine’s Patent 1000, and recognized in The Legal 500 “United States for Healthcare: Life Sciences”.
- Santa Clara University (JD, cum laude)
- Johns Hopkins University (PhD, Cellular and Molecular Medicine)
- Rice University (BA, Biochemistry)
Recognition & Awards
- Selected as law firm honoree in the Collaborative Leadership category of Corporate Counsel’s Women, Influence & Power in Law Awards (2020)
- Selected as one of the 100 Most Influential Women in Business in the Bay Area by the San Francisco Business Times (2020)
- Recognized by The Legal 500 United States for Healthcare: Life Sciences (2019 - 2020)
- Identified in the IAM Patent 1000, a listing of the “World’s Leading Patent Practitioners” (2020)